Vanda Pharmaceuticals Equity 2024

Vanda Pharmaceuticals Aktienanalyse

What does Vanda Pharmaceuticals do?

Vanda Pharmaceuticals Inc is a US biotechnology company specializing in the development and marketing of innovative therapies for neurological, psychiatric, and cardiovascular diseases. It was founded in 2002 by Mihael H. Polymeropoulos, who previously worked as a senior researcher at the genetic research company Novartis. Vanda Pharmaceuticals is based in Washington D.C. The company's business model focuses on developing and bringing to market medicines for rare diseases. It collaborates closely with clinics and research institutes to tailor innovative therapies and medications to the specific needs of patients. Vanda Pharmaceuticals operates in various areas, including neurology, psychiatry, and cardiology. In neurology, the company focuses on researching and developing therapies for rare diseases such as isolated sleeplessness syndrome and delayed sleep phase syndrome. In psychiatry, Vanda Pharmaceuticals has brought several medications to market for the treatment of schizophrenia, bipolar disorder, and depression. The medication Fanapt, in particular, has become a successful schizophrenia medication and has already been approved by the US FDA. In cardiology, Vanda Pharmaceuticals is working on the development of medications for the treatment of cardiovascular diseases such as heart failure and high blood pressure. One of Vanda Pharmaceuticals' most innovative therapy forms is chronotherapy, which involves timing the intake of certain medications to the body's natural circadian rhythm. The goal of chronotherapy is to maximize treatment effectiveness while minimizing side effects. An example of Vanda Pharmaceuticals' successes is the aforementioned medication Fanapt, which was approved by the FDA in 2009 and is distributed worldwide. Clinical studies have shown that Fanapt is safe and effective in the treatment of schizophrenia. The high expectations for the medication have led to Vanda Pharmaceuticals' listing on the NASDAQ and the company having a market value of several hundred million dollars. In conclusion, Vanda Pharmaceuticals is an innovative biotechnology company specializing in the research and development of therapies for rare diseases. With the successful introduction of medications like Fanapt, the company has established itself as an important player in the American and international markets. Vanda Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Vanda Pharmaceuticals's Equity

Vanda Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Vanda Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Vanda Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Vanda Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Vanda Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Vanda Pharmaceuticals stock

What is the equity of Vanda Pharmaceuticals this year?

Vanda Pharmaceuticals has equity of 544.91 M USD this year.

What was the equity of Vanda Pharmaceuticals compared to the previous year?

The equity of Vanda Pharmaceuticals has increased/decreased by 3.36% increased compared to the previous year.

What impact does a high equity have on investors of Vanda Pharmaceuticals?

A high equity is advantageous for investors of Vanda Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Vanda Pharmaceuticals?

A low equity can be a risk for investors of Vanda Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Vanda Pharmaceuticals affect the company?

An increase in equity of Vanda Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Vanda Pharmaceuticals affect the company?

A reduction in equity of Vanda Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Vanda Pharmaceuticals?

Some factors that can affect the equity of Vanda Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Vanda Pharmaceuticals so important for investors?

The equity of Vanda Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Vanda Pharmaceuticals take to change the equity?

To change equity, Vanda Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Vanda Pharmaceuticals pay?

Over the past 12 months, Vanda Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vanda Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Vanda Pharmaceuticals?

The current dividend yield of Vanda Pharmaceuticals is .

When does Vanda Pharmaceuticals pay dividends?

Vanda Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vanda Pharmaceuticals?

Vanda Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Vanda Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vanda Pharmaceuticals located?

Vanda Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vanda Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vanda Pharmaceuticals from 9/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.

When did Vanda Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/19/2024.

What was the dividend of Vanda Pharmaceuticals in the year 2023?

In the year 2023, Vanda Pharmaceuticals distributed 0 USD as dividends.

In which currency does Vanda Pharmaceuticals pay out the dividend?

The dividends of Vanda Pharmaceuticals are distributed in USD.